- Lifeline Skin Care products contain parthenogenetic stem cell extract delivering skin rejuvenation technology that could help, prevent and repair damaged skin?
The Bottom Line: Lifeline Skin Care is now ready to move forward to the next phase of distribution, which will commence 4/11. Sales to date have greatly exceeded expectations for the trial launch. The phase will consist initially of a customer solicitation conducted by internet and direct response marketing. We agree with Ken Aldrich, Chairman of ISCO; selling over 7,000 bottles through a very limited trial launch, represents a first step, but it would be imprudent to base projections of future sales or profits on a sample base of this size. ISCO.OB is up $0.14 to $1.48 or 10.45%.